Small-cell lung cancer (SCLC), sometimes called small-cell carcinoma, causes about 10%-15% of all lung cancer. Non-small-cell lung cancer (NSCLC) causes the rest. 2 Types of SCLC ...

In invasive lung carcinomas, including non-small cell lung cancer (NSCLC), the TMB ranges from 10 to nearly 1,000 mutations per million bases of exonic (i.e., protein-coding) DNA sequence; for ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, ... Risks and Causes of Lung Cancer. Cancer Research UK. March 14, 2023. Zhang X et al.

Non-small cell lung cancer (NSCLC) is a type of cancer that begins in the tissues of the lungs. About 80-85% of all lung cancer cases in the United States are classified as NSCLC.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.

Memorial Sloan Kettering Cancer Center. "New, rare type of small cell lung cancer identified." ScienceDaily. ScienceDaily, 11 September 2024. <www.sciencedaily.com / releases / 2024 / 09 ...

Topline data were announced from a phase 3 trial evaluating tarlatamab-dlle (Imdelltra ®) for the treatment of small cell lung cancer (SCLC) in patients who progressed on or after a single line ...

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.